These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37612090)

  • 21. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.
    Mason WP; Graus F; Lang B; Honnorat J; Delattre JY; Valldeoriola F; Antoine JC; Rosenblum MK; Rosenfeld MR; Newsom-Davis J; Posner JB; Dalmau J
    Brain; 1997 Aug; 120 ( Pt 8)():1279-300. PubMed ID: 9278623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myositis induced by durvalumab in a patient with non-small cell lung cancer: A case report.
    Kobayashi M; Saiki M; Omori C; Ide S; Masuda K; Sogami Y; Hata T; Ishihara H
    Thorac Cancer; 2020 Dec; 11(12):3614-3617. PubMed ID: 33103845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer.
    Shibata Y; Murakami S
    Expert Opin Drug Saf; 2020 Jun; 19(6):653-659. PubMed ID: 32357806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
    Tao H; Li F; Li R; Han X; Hu Y
    Ann Palliat Med; 2020 Sep; 9(5):3623-3628. PubMed ID: 32648466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
    Graus F; Dalmau J
    Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer: A case report.
    Gong S; Han Y; He E; Liu M; Fu X; Deng F
    Front Immunol; 2022; 13():955170. PubMed ID: 35967304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
    Raspotnig M; Vedeler C; Storstein A
    J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
    Cuzzubbo S; Javeri F; Tissier M; Roumi A; Barlog C; Doridam J; Lebbe C; Belin C; Ursu R; Carpentier AF
    Eur J Cancer; 2017 Mar; 73():1-8. PubMed ID: 28064139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paraneoplastic neurological syndrome as an initial indicator of small cell carcinoma of the lung.
    Porto L; Miranda M; Gomes A; André R; Rodrigues B
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23391962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Following sensory neuropathy, anti-Hu antibody-positive paraneoplastic neurological syndrome presenting with limbic encephalitis occurs after complete remission].
    Fukami Y; Umemura T; Shimono T; Yokoi T; Kamijo M; Sakakibara T
    Rinsho Shinkeigaku; 2013; 53(4):287-92. PubMed ID: 23603543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-SOX1 antibodies-positive paraneoplastic neurological syndromes caused by thyroid carcinoma: A case report.
    Deng Y; Zhang X; Wang L; Lu X; Gao Y; Wu Z; Zhong Z
    Medicine (Baltimore); 2023 Apr; 102(16):e33499. PubMed ID: 37083806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraneoplastic Optic Neuropathy Associated With Purkinje Cell Antibody-2 in a Patient With Small Cell Lung Cancer.
    Micieli JA; Margolin EA
    J Neuroophthalmol; 2017 Mar; 37(1):53-55. PubMed ID: 27759576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.
    Domblides M; Geier M; Decroisette C; Descourt R
    Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paraneoplastic neurological syndromes in patients affected by SCLC: a case series.
    Zanella C; Leone AG; Zambelli L; Bottiglieri A; Canziani L; Brambilla M; Lo Russo G; Platania M; De Braud F; Occhipinti M
    Tumori; 2022 Dec; 108(6):NP11-NP14. PubMed ID: 35260015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paraneoplastic neurological syndrome in a patient with squamous cell lung cancer.
    Mori H; Yamada O; Ohno Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Funaguchi N; Minatoguchi S
    Intern Med; 2013; 52(17):1967-70. PubMed ID: 23994993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-Hu antibody positive sensory neuronopathy causing painful legs and moving toes (PLMT) in a 75-year-old female with small cell lung cancer (SCLC)].
    Tsujimoto Y; Hao A; Sato T; Hideyama T; Shibuya H; Shiio Y
    Rinsho Shinkeigaku; 2018 Nov; 58(11):677-681. PubMed ID: 30369526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.